About Century Therapeutics
Century Therapeutics is a company based in Philadelphia (United States) founded in 2018. Century Therapeutics has raised $410 million across 4 funding rounds from investors including Fidelity Investments, Marshall Wace and FUJIFILM Cellular Dynamics. The company has 150 employees as of December 31, 2024. Century Therapeutics has completed 3 acquisitions, including Clade TX, Empirica Therapeutics and empirica. Century Therapeutics offers products and services including iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.
- Headquarter Philadelphia, United States
- Employees 150 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Century Therapeutics, Inc.
-
Annual Revenue
$6.59 M (USD)194.81as on Dec 31, 2024
-
Net Profit
-$126.57 M (USD)7.4as on Dec 31, 2024
-
EBITDA
-$120.97 M (USD)-7.87as on Dec 31, 2024
-
Total Equity Funding
$410 M (USD)
in 4 rounds
-
Latest Funding Round
$135 M (USD), Post-IPO
Jan 08, 2026
-
Investors
Fidelity Investments
& 23 more
-
Employee Count
150
as on Dec 31, 2024
-
Investments & Acquisitions
Clade TX
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Century Therapeutics
Century Therapeutics is a publicly listed company on the NASDAQ with ticker symbol IPSC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Century Therapeutics
Century Therapeutics offers a comprehensive portfolio of products and services, including iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.
Engineered cells for cancer treatment through immune response.
Therapies targeting autoimmune diseases via cellular engineering.
People of Century Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Century Therapeutics
Century Therapeutics has successfully raised a total of $410M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $135 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Century Therapeutics
Century Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Marshall Wace and FUJIFILM Cellular Dynamics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Locked | Locked | Locked | |
|
Investment firm focused on global life sciences and healthcare.
|
Locked | Locked | Locked |
Investor details for Century Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Century Therapeutics
Century Therapeutics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Clade TX, Empirica Therapeutics and empirica.
Investment portfolio details for Century Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Stem cell-derived therapies for cancer are developed using pluripotent cells.
|
Locked | Locked | 2020 | Locked | |
|
T-cell therapeutics are developed for brain cancer treatment.
|
Locked | Locked | 2018 | Locked | |
|
Research and consulting services are provided by empirica.
|
Locked | Locked | 1988 | Locked |
Complete acquisition details for Century Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Century Therapeutics
Detailed financials for Century Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Century Therapeutics Comparisons
Peer comparison for Century Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Century Therapeutics
Detailed competitors of Century Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Century Therapeutics
Complete news archive for Century Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Century Therapeutics
Century Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Century Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Century Therapeutics is a funded company, having raised a total of $410M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Century Therapeutics is 150.
Annual revenue of Century Therapeutics is $6.59M as on Dec 31, 2024.
Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, United States. Operations focus on the biotechnology sector, where adult stem cells are harnessed to create therapies targeting cancer. Novel allogeneic living drugs for oncology are being developed to address shortcomings in first-generation cell therapies. The companys efforts center on advancing these cellular treatments through research and development processes.
Century Therapeutics offers iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.
Yes, Century Therapeutics is publicly traded on NASDAQ under the ticker symbol IPSC.
Century Therapeutics has made 3 acquisitions, including Clade TX, Empirica Therapeutics, and empirica.
Century Therapeutics has 24 investors. Key investors include Fidelity Investments, Marshall Wace, FUJIFILM Cellular Dynamics, Orbimed, and RA Capital.
The ticker symbol of Century Therapeutics is IPSC on NASDAQ.